OBJECTIVE: To estimate and identify factors associated with the incidence of all-cause end-stage renal disease (ESRD) among newly diagnosed systemic lupus erythematosus (SLE) patients. METHODS: Data from a national registry of treated ESRD were linked to data from a lupus registry of SLE patients who were newly diagnosed and living in Atlanta, Georgia, 2002-2004 (median followup 7.8 years). Cumulative incidence and incidence rates (ESRD treatment initiations per 1,000 patient-years) were calculated, and age- and race-adjusted Poisson models were used to calculate incidence rate ratios (IRRs). RESULTS: Among 344 newly diagnosed SLE patients, 29 initiated ESRD treatment over 2,603.8 years of followup. Incidence rates were 13.8 (95% confidence interval [95% CI] 9.4-20.3) among black patients and 3.3 (95% CI 0.8-13.0) among white patients, per 1,000 patient-years; corresponding 5-year cumulative incidence was 6.4% and 2.5% among black and white patients, respectively. Lupus nephritis documented prior to 2005, which occurred in 80% of those who progressed to ESRD, was the strongest risk factor for incident ESRD (IRR 6.7 [95% CI 2.7-16.8]; incidence rate 27.6 per 1,000 patient-years). Results suggested that patients who were black versus white (IRR 3.9 [95% CI 0.9-16.4]) or <18 years old (versus ≥30 years old) at diagnosis (IRR 2.1 [95% CI 0.9-5.3]) may be more likely to progress to ESRD, but incidence did not differ by sex or other characteristics. CONCLUSION: The incidence of all-cause ESRD among patients with a recent diagnosis of SLE is high in Georgia. Interventions to decrease ESRD incidence among newly diagnosed SLE patients should target young and black patients, as well as patients with lupus nephritis.
OBJECTIVE: To estimate and identify factors associated with the incidence of all-cause end-stage renal disease (ESRD) among newly diagnosed systemic lupus erythematosus (SLE) patients. METHODS: Data from a national registry of treated ESRD were linked to data from a lupus registry of SLEpatients who were newly diagnosed and living in Atlanta, Georgia, 2002-2004 (median followup 7.8 years). Cumulative incidence and incidence rates (ESRD treatment initiations per 1,000 patient-years) were calculated, and age- and race-adjusted Poisson models were used to calculate incidence rate ratios (IRRs). RESULTS: Among 344 newly diagnosed SLEpatients, 29 initiated ESRD treatment over 2,603.8 years of followup. Incidence rates were 13.8 (95% confidence interval [95% CI] 9.4-20.3) among black patients and 3.3 (95% CI 0.8-13.0) among white patients, per 1,000 patient-years; corresponding 5-year cumulative incidence was 6.4% and 2.5% among black and white patients, respectively. Lupus nephritis documented prior to 2005, which occurred in 80% of those who progressed to ESRD, was the strongest risk factor for incident ESRD (IRR 6.7 [95% CI 2.7-16.8]; incidence rate 27.6 per 1,000 patient-years). Results suggested that patients who were black versus white (IRR 3.9 [95% CI 0.9-16.4]) or <18 years old (versus ≥30 years old) at diagnosis (IRR 2.1 [95% CI 0.9-5.3]) may be more likely to progress to ESRD, but incidence did not differ by sex or other characteristics. CONCLUSION: The incidence of all-cause ESRD among patients with a recent diagnosis of SLE is high in Georgia. Interventions to decrease ESRD incidence among newly diagnosed SLEpatients should target young and black patients, as well as patients with lupus nephritis.
Authors: S Sam Lim; Cristina Drenkard; W Joseph McCune; Charles G Helmick; Caroline Gordon; Peter Deguire; Rana Bayakly; Emily C Somers Journal: Arthritis Rheum Date: 2009-10-15
Authors: S Bernatsky; J-F Boivin; L Joseph; S Manzi; E Ginzler; D D Gladman; M Urowitz; P R Fortin; M Petri; S Barr; C Gordon; S-C Bae; D Isenberg; A Zoma; C Aranow; M-A Dooley; O Nived; G Sturfelt; K Steinsson; G Alarcón; J-L Senécal; M Zummer; J Hanly; S Ensworth; J Pope; S Edworthy; A Rahman; J Sibley; H El-Gabalawy; T McCarthy; Y St Pierre; A Clarke; R Ramsey-Goldman Journal: Arthritis Rheum Date: 2006-08
Authors: María J Molina; Angel M Mayor; Alejandro E Franco; Carlos A Morell; Miguel A López; Luis M Vilá Journal: J Clin Rheumatol Date: 2007-08 Impact factor: 3.517
Authors: Guillermo J Pons-Estel; Graciela S Alarcón; Gerald McGwin; Maria I Danila; Jie Zhang; Holly M Bastian; John D Reveille; Luis M Vilá Journal: Arthritis Rheum Date: 2009-06-15
Authors: Graciela S Alarcón; Gerald McGwin; Michelle Petri; Rosalind Ramsey-Goldman; Barri J Fessler; Luis M Vilá; Jeffrey C Edberg; John D Reveille; Robert P Kimberly Journal: PLoS Med Date: 2006-10 Impact factor: 11.069
Authors: David H Chae; Connor D Martz; Thomas E Fuller-Rowell; Erica C Spears; Tianqi Tenchi Gao Smith; Evelyn A Hunter; Cristina Drenkard; S Sam Lim Journal: Am J Epidemiol Date: 2019-08-01 Impact factor: 4.897
Authors: Federica Genovese; Ahmad Akhgar; Sung Sam Lim; Alton B Farris; Monica Battle; Jason Cobb; Dominic Sinibaldi; Morten A Karsdal; Wendy I White Journal: Kidney360 Date: 2021-06-18
Authors: Titilayo O Ilori; Nosayaba Enofe; Anju Oommen; Jason Cobb; Jose Navarrete; Demilade A Adedinsewo; Oluwatobiloba Oshikoya; Helene Fevrier; Alton B Farris; Laura Plantinga; Akinlolu O Ojo Journal: PLoS One Date: 2016-06-15 Impact factor: 3.240
Authors: Jorge Ivan Gamez-Nava; Valeria Diaz-Rizo; Edsaul Emilio Perez-Guerrero; Jose Francisco Muñoz-Valle; Ana Miriam Saldaña-Cruz; Nicte Selene Fajardo-Robledo; Heriberto Jacobo-Cuevas; Cesar Arturo Nava-Valdivia; Miriam Fabiola Alcaraz-Lopez; Xochitl Trujillo; Miguel Huerta; Ernesto German Cardona-Muñoz; Laura Gonzalez-Lopez Journal: Biomark Res Date: 2020-10-28